keyword
MENU ▼
Read by QxMD icon Read
search

ADT

keyword
https://www.readbyqxmd.com/read/29777382/mood-sexuality-and-relational-intimacy-after-starting-androgen-deprivation-therapy-implications-for-couples
#1
Lauren M Walker, Pablo Santos-Iglesias, John Robinson
BACKGROUND: Patients on androgen deprivation therapy (ADT), a common treatment for prostate cancer, report significant declines in quality of life and detrimental impact on their intimate relationships. ADT depresses a man's testosterone to castrate levels, leading to declines in sexual function, and changes in mood. These changes can have profound impact on couples' intimate relationships. METHOD: Patients undergoing ADT, and their consenting partners, were followed on a variety of outcomes relating to mood, sexual changes, and relational intimacy...
May 18, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29773851/modeling-transcriptional-rewiring-in-neutrophils-through-the-course-of-treated-juvenile-idiopathic-arthritis
#2
Zihua Hu, Kaiyu Jiang, Mark Barton Frank, Yanmin Chen, James N Jarvis
Neutrophils in children with the polyarticular form of juvenile idiopathic arthritis (JIA) display abnormal transcriptional patterns linked to fundamental metabolic derangements. In this study, we sought to determine the effects of therapy on mRNA and miRNA expression networks in polyarticular JIA. Using exon and miRNA microarrays, we studied children with untreated active JIA (ADU, n = 35), children with active disease on therapy with methotrexate ± etanercept (ADT, n = 26), and children with inactive disease also on therapy (ID, n = 14)...
May 17, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29772726/an-alternative-lifetime-model-for-white-light-emitting-diodes-under-thermal%C3%A2-electrical-stresses
#3
Xi Yang, Bo Sun, Zili Wang, Cheng Qian, Yi Ren, Dezhen Yang, Qiang Feng
The lifetime prediction using accelerated degradation test (ADT) method has become a main issue for white light emitting diodes applications. This paper proposes a novel lifetime model for light emitting diodes (LEDs) under thermal and electrical stresses, where the junction temperature and driving current are deemed the input parameters for lifetime prediction. The features of LEDs' lifetime and the law of lumen depreciation under dual stresses are combined to build the lifetime model. The adoption of thermal and electrical stresses overcomes the limitation of single stress, and junction temperature in accelerated degradation test as thermal stress is more reliable than ambient temperature in conventional ADT...
May 16, 2018: Materials
https://www.readbyqxmd.com/read/29772100/radical-prostatectomy-in-t4-prostate-cancer-after-inductive-androgen-deprivation-results-of-a-single-institution-series-with-long-term-follow-up
#4
Turkan Hajili, Carsten H Ohlmann, Johannes Linxweiler, Christina Niklas, Martin Janssen, Stefan Siemer, Michael Stoeckle, Matthias Saar
OBJECTIVES: To determine the outcomes of complete surgical resection of T4 prostate cancer (PCa) after inductive androgen deprivation treatment (ADT). An inductive ADT and subsequent radical prostatectomy (RP) is not recommended by any guideline yet. PATIENTS AND METHODS: A monocentric RP database was queried for patients initially diagnosed with T4 PCa, considered as primary inoperable because of a fixed mass defined by rectal examination in combination with high PSA and/or large foci of biopsy-proven undifferentiated PCa...
May 17, 2018: BJU International
https://www.readbyqxmd.com/read/29761176/androgen-deprivation-therapy-is-associated-with-prolongation-of-qtc-interval-in-men-with-prostate-cancer
#5
Thiago Gagliano-Jucá, Thomas G Travison, Philip W Kantoff, Paul L Nguyen, Mary-Ellen Taplin, Adam S Kibel, Grace Huang, Richelle Bearup, Haley Schram, Robert Manley, Yusnie M Beleva, Robert R Edwards, Shehzad Basaria
Context: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with increased cardiovascular mortality and sudden cardiac death, with some events occurring early after initiation of ADT. Testosterone levels are inversely associated with corrected QT (QTc) interval duration; therefore, prolongation of QTc duration could be responsible for some of these events during ADT. Objective: To evaluate changes in QTc duration during ADT. Design and Interventions: A 6-month prospective cohort study that enrolled men with PCa about to undergo ADT (ADT group) and a control group of men who previously underwent prostatectomy for PCa and never received ADT (non-ADT group)...
May 1, 2018: Journal of the Endocrine Society
https://www.readbyqxmd.com/read/29760221/development-and-validation-of-a-prostate-cancer-genomic-signature-that-predicts-early-adt-treatment-response-following-radical-prostatectomy
#6
Mohammed Alshalalfa, R Jeffrey Karnes, Vidit Sharma, Voleak Choeurng, Hussam Al-Deen Ashab, Nicholas Erho, Bruce J Trock, Ashley E Ross, Kasra Yousefi, Harrison K Tsai, Shuang G Zhao, Jeffrey J Tosoian, Zaid Haddad, Mandeep Takhar, S Laura Chang, Daniel E Spratt, Firas Abdollah, Robert B Jenkins, Eric A Klein, Paul L Nguyen, Adam P Dicker, Robert B Den, Elai Davicioni, Felix Y Feng, Tamara L Lotan, Edward M Schaeffer
PURPOSE: Currently no genomic signature exists to distinguish men most likely to progress on adjuvant androgen deprivation therapy (ADT) after radical prostatectomy (RP) for high risk prostate cancer. Here we develop and validate a gene expression signature to predict response to postoperative ADT. EXPERIMENTAL DESIGN: A training set consisting of 284 RP patients was established after 1:1 propensity score matching metastasis between adjuvant-ADT(a-ADT) treated and no-ADT treated groups...
May 14, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29757368/the-long-noncoding-rna-landscape-of-neuroendocrine-prostate-cancer-and-its-clinical-implications
#7
Varune Rohan Ramnarine, Mohammed Alshalalfa, Fan Mo, Noushin Nabavi, Nicholas Erho, Mandeep Takhar, Robert Shukin, Sonal Brahmbhatt, Alexander Gawronski, Maxim Kobelev, Mannan Nouri, Dong Lin, Harrison Tsai, Tamara L Lotan, R Jefferey Karnes, Mark A Rubin, Amina Zoubeidi, Martin E Gleave, Cenk Sahinalp, Alexander W Wyatt, Stanislav V Volik, Himisha Beltran, Elai Davicioni, Yuzhuo Wang, Colin C Collins
Background: Treatment induced neuroendocrine prostate cancer (tNEPC) is an aggressive variant of late-stage metastatic castrate resistant (mCRPC) prostate cancer that commonly arises through neuroendocrine transdifferentiation (NEtD). Treatment options are limited, ineffective, and for most patients, results in death in less than a year. We previously developed a first-in-field patient-derived xenograft (PDX) model of NEtD. Longitudinal deep transcriptome profiling of this model enabled monitoring of dynamic transcriptional changes during NEtD and in the context of androgen deprivation...
May 10, 2018: GigaScience
https://www.readbyqxmd.com/read/29752513/oligorecurrent-prostate-cancer-limited-to-lymph-nodes-getting-our-ducks-in-a-row
#8
Andrei Fodor, Andrea Lancia, Francesco Ceci, Maria Picchio, Morten Hoyer, Barbara Alicja Jereczek-Fossa, Piet Ost, Paolo Castellucci, Elena Incerti, Nadia Di Muzio, Gianluca Ingrosso
PURPOSE: Oligorecurrent prostate cancer with exclusive nodal involvement represents a common state of disease, amenable to local therapy. New radio-labeled tracers have enriched the possibility of cancer detection and treatment. In this review, we aim to illustrate the main nuclear medicine diagnostic options and the role of radiotherapy in this setting of patients. METHODS: We performed a PubMed search referring to the PRISMA guidelines to analyze the performance of PSMA- and choline-PET in detecting oligorecurrence limited to lymph nodes, and to review the main studies supporting either ablative stereotactic body radiotherapy or regional lymph node irradiation in this clinical setting...
May 11, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29750646/circulating-steroid-levels-as-correlates-of-adipose-tissue-phenotype-in-premenopausal-women
#9
Geneviève B Marchand, Anne-Marie Carreau, Sofia Laforest, Julie-Anne Côté, Marleen Daris, Katherine Cianflone, Cornelia Prehn, Jerzy Adamski, André Tchernof
Background Obesity-related alterations in the circulating steroid hormone profile remain equivocal in women. Our objective was to identify circulating steroid levels that relate to increased adiposity and altered adipose phenotype in premenopausal women. Materials and methods In a sample of 42 premenopausal women [age 46 ± 3 years; body mass index (BMI) 27.1 ± 4.2 kg/m2], 19 plasma steroids were quantified by electrospray ionization-liquid chromatography-tandem mass spectroscopy (ESI-LC-MS/MS). Body composition and fat distribution were assessed by dual-energy X-ray absorptiometry (DXA) and computed tomography (CT), respectively...
May 11, 2018: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/29750398/body-composition-fatigue-and-exercise-in-patients-with-prostate-cancer-undergoing-androgen-deprivation-therapy
#10
Robert U Newton, Emily Jeffery, Daniel A Galvão, Carolyn McIntyre, Nigel Spry, David Joseph, Jim Denham, Dennis R Taaffe
OBJECTIVES: To investigate the association between lean mass (LM) and fat mass (FM) with fatigue and vitality before and following exercise in patients with prostate cancer already undergoing androgen deprivation therapy (ADT). SUBJECTS AND METHODS: Cross-sectional associations between lean and fat mass with fatigue and/or vitality measures were examined in 229 patients (43-90 years). Prospective analysis was undertaken in 129 patients who underwent 3-6 months exercise (predominantly resistance + aerobic)...
May 11, 2018: BJU International
https://www.readbyqxmd.com/read/29748958/functional-roles-and-potential-clinical-application-of-mirna-345-5p-in-prostate-cancer
#11
Ilker Tinay, Mingyue Tan, Bin Gui, Lillian Werner, Adam S Kibel, Li Jia
BACKGROUND: MicroRNAs (miRNAs) are small non-coding RNAs, which negatively regulate gene expression and impact prostate cancer (PCa) growth and progression. Circulating miRNAs are stable and detectable in cell-free body fluids, such as serum. Investigation of circulating miRNAs presents great potential in uncovering new insights into the roles of miRNAs in PCa diagnosis and therapy. METHODS: Using TaqMan miRNA quantitative reverse transcription polymerase chain reaction (RT-qPCR), we compared the expression levels of five miRNAs (miR-193a-3p, miR-9-3p, miR-335-5p, miR-330-3p, and miR-345-5p) in serum samples from 20 normal individuals without cancer, 25 patients with localized disease, 25 patients with hormone-naïve or hormone sensitive metastatic disease, and 25 patients with metastatic castration-resistant prostate cancer (CRPC)...
May 10, 2018: Prostate
https://www.readbyqxmd.com/read/29748830/-give-me-five-ultra-hypofractionated-radiotherapy-for-localized-prostate-cancer-non-invasive-ablative-approach
#12
Giulia Marvaso, Giulia Riva, Delia Ciardo, Sara Gandini, Cristiana Fodor, Dario Zerini, Sarah Pia Colangione, Giorgia Timon, Stefania Comi, Raffaella Cambria, Federica Cattani, Ottavio De Cobelli, Roberto Orecchia, Barbara A Jereczek-Fossa
Ultra-hypofractionated radiotherapy (RT) is given over a shorter time with larger doses with respect to conventional fractionation in patients with localized prostate cancer (PCa). The use of hypofractionation is supported both from the radiobiological point of view (the low α/β-ratio in PCa and dose escalation) and from the rising number of clinical evidences. The aim of this study is to review our data regarding oncological outcomes, namely biochemical progression-free survival (b-PFS) and clinical progression-free survival (c-PFS), acute and long-term toxicities in patients treated with a ultra-hypofractionated RT...
May 10, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29739368/impact-of-early-changes-in-serum-biomarkers-following-androgen-deprivation-therapy-on-clinical-outcomes-in-metastatic-hormone-sensitive-prostate-cancer
#13
Hiromi Sato, Shintaro Narita, Norihiko Tsuchiya, Atsushi Koizumi, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Shigeru Satoh, Kyoko Nomura, Tomonori Habuchi
BACKGROUND: Less evidence is known about the role of early changes in serum biomarker after androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Here we evaluated the impact of pre-treatment prognostic factors and early changes in serum biomarkers on prostate specific antigen (PSA) progression-free and overall survival rates in mHSPC. METHODS: We retrospectively reviewed the medical records of 60 mHSPC patients (median age 72 years) treated with ADT whose laboratory data at baseline and following 12 weeks were available...
May 8, 2018: BMC Urology
https://www.readbyqxmd.com/read/29735818/treatment-strategy-for-metastatic-prostate-cancer-with-extremely-high-psa-level-reconsidering-the-value-of-vintage-therapy
#14
Yasutaka Yamada, Shinichi Sakamoto, Yoshiyasu Amiya, Makoto Sasaki, Takayuki Shima, Akira Komiya, Noriyuki Suzuki, Koichiro Akakura, Tomohiko Ichikawa, Hiroomi Nakatsu
The prognostic significance of initial prostate-specific antigen (PSA) level for metastatic prostate cancer remains uncertain. We investigated the differences in prognosis and response to hormonal therapies of metastatic prostate cancer patients according to initial PSA levels. We analyzed 184 patients diagnosed with metastatic prostate cancer and divided them into three PSA level groups as follows: low (<100 ng ml-1 ), intermediate (100-999 ng ml-1 ), and high (≥1000 ng ml-1 ). All patients received androgen deprivation therapy (ADT) immediately...
May 4, 2018: Asian Journal of Andrology
https://www.readbyqxmd.com/read/29734647/recent-advances-in-prostate-cancer-treatment-and-drug-discovery
#15
REVIEW
Ekaterina Nevedomskaya, Simon J Baumgart, Bernard Haendler
Novel drugs, drug sequences and combinations have improved the outcome of prostate cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and apalutamide which target androgen receptor (AR) signaling, radium-223 dichloride for reduction of bone metastases, sipuleucel-T immunotherapy and taxane-based chemotherapy. Adding abiraterone acetate to androgen deprivation therapy (ADT) in order to achieve complete androgen blockade has proven highly beneficial for treatment of locally advanced prostate cancer and metastatic hormone-sensitive prostate cancer (mHSPC)...
May 4, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29719883/nursing-information-flow-in-long-term-care-facilities
#16
Quan Wei, Karen L Courtney
OBJECTIVE:  Long-term care (LTC), residential care requiring 24-hour nursing services, plays an important role in the health care service delivery system. The purpose of this study was to identify the needed clinical information and information flow to support LTC Registered Nurses (RNs) in care collaboration and clinical decision making. METHODS:  This descriptive qualitative study combines direct observations and semistructured interviews, conducted at Alberta's LTC facilities between May 2014 and August 2015...
April 2018: Applied Clinical Informatics
https://www.readbyqxmd.com/read/29712718/persisting-adverse-body-composition-changes-2-years-after-cessation-of-androgen-deprivation-therapy-for-localised-prostate-cancer
#17
Ada S Cheung, Alistair Tinson, Stefan Milevski, Rudolf Hoermann, Jd Zajac, Mathis Grossmann
OBJECTIVE: Hypogonadism from androgen deprivation therapy (ADT) for prostate cancer causes adverse body composition changes associated with insulin resistance and decreased quality of life (QoL). Our objective was to assess whether adverse body composition changes improve after cessation of ADT. DESIGN: Prospective case-control study in a tertiary referral hospital. Thirty-four men newly commencing ADT (cases, median age 67.6 years [interquartile range 64.6, 72...
April 30, 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29709664/outcomes-and-prognostic-factors-in-men-receiving-androgen-deprivation-therapy-for-prostate-cancer-recurrence-after-radical-prostatectomy
#18
Praful Ravi, R Jeffrey Karnes, Laureano J Rangel, Lance C Pagliaro
PURPOSE: To determine clinicopathologic factors associated with early progression on androgen deprivation therapy (ADT) as well as cancer-specific (CSS) and overall survival (OS), and assess whether certain prostate specific antigen (PSA) thresholds at ADT initiation are associated with poorer outcomes. METHODS: 2418 men with rising PSA after undergoing radical prostatectomy at a single institution between 1987-2007 were identified from a prospectively-maintained registry...
April 27, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29707793/interleukin-6-induces-vegf-secretion-from-prostate-cancer-cells-in-a-manner-independent-of-androgen-receptor-activation
#19
Kenichiro Ishii, Takeshi Sasaki, Kazuhiro Iguchi, Shinya Kajiwara, Manabu Kato, Hideki Kanda, Yoshifumi Hirokawa, Kiminobu Arima, Atsushi Mizokami, Yoshiki Sugimura
BACKGROUND: The reduced androgen-sensitivity of prostate cancer (PCa) cells is an important clinical development because of its association with the cells' progression to castration-resistant prostate cancer (CRPC). During androgen deprivation therapy (ADT), stroma-derived growth factors and cytokines can activate the androgen receptor (AR). For example, IL-6 is a multifunctional cytokine that is involved in the malignancy of PCa cells through AR activation. In the present study, we used an androgen-sensitive human PCa cell line (LNCaP) and its sublines to investigate the relationship between the responsiveness of PCa cells to IL-6 treatment and the cellular AR signaling pathway...
April 29, 2018: Prostate
https://www.readbyqxmd.com/read/29707790/time-of-metastatic-disease-presentation-and-volume-of-disease-are-prognostic-for-metastatic-hormone-sensitive-prostate-cancer-mhspc
#20
Edoardo Francini, Kathryn P Gray, Wanling Xie, Grace K Shaw, Loana Valença, Brandon Bernard, Laurence Albiges, Lauren C Harshman, Philip W Kantoff, Mary-Ellen Taplin, Cristopher J Sweeney
BACKGROUND: Currently, there is no universally accepted prognostic classification for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT). Subgroup analyses demonstrated that pts with low volume (LV), per CHAARTED trial definition, mHSPC, and those who relapse after prior local therapy (PLT) have longer overall survival (OS) compared to high volume (HV) and de-novo (DN), respectively. Using a hospital-based registry, we aimed to assess whether a classification based on time of metastatic disease (PLT vs DN) and disease volume (LV vs HV) are prognostic for mHSPC pts treated with ADT...
April 29, 2018: Prostate
keyword
keyword
58121
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"